Lazard Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $953K | Sell |
43,969
-129,257
| -75% | -$2.8M | ﹤0.01% | 1316 |
|
|
2025
Q1 | $4.2M | Buy |
173,226
+47,883
| +38% | +$1.16M | 0.01% | 733 |
|
|
2024
Q4 | $2.61M | Buy |
125,343
+46,318
| +59% | +$966K | ﹤0.01% | 794 |
|
|
2024
Q3 | $1.57M | Buy |
79,025
+56,144
| +245% | +$1.12M | ﹤0.01% | 932 |
|
|
2024
Q2 | $353K | Sell |
22,881
-7,453
| -25% | -$115K | ﹤0.01% | 1343 |
|
|
2024
Q1 | $482K | Buy |
30,334
+8,133
| +37% | +$129K | ﹤0.01% | 1066 |
|
|
2023
Q4 | $373K | Buy |
22,201
+1,127
| +5% | +$18.9K | ﹤0.01% | 1197 |
|
|
2023
Q3 | $246K | Buy |
21,074
+3,078
| +17% | +$35.9K | ﹤0.01% | 1314 |
|
|
2023
Q2 | $241K | Sell |
17,996
-5,182
| -22% | -$69.4K | ﹤0.01% | 1296 |
|
|
2023
Q1 | $384K | Sell |
23,178
-16,980
| -42% | -$281K | ﹤0.01% | 1157 |
|
|
2022
Q4 | $746K | Buy |
40,158
+17,032
| +74% | +$316K | ﹤0.01% | 1047 |
|
|
2022
Q3 | $296K | Buy |
23,126
+418
| +2% | +$5.35K | ﹤0.01% | 1189 |
|
|
2022
Q2 | $159K | Sell |
22,708
-47,567
| -68% | -$333K | ﹤0.01% | 1341 |
|
|
2022
Q1 | $582K | Buy |
70,275
+62,901
| +853% | +$521K | ﹤0.01% | 1081 |
|
|
2021
Q4 | $49K | Sell |
7,374
-1,441
| -16% | -$9.58K | ﹤0.01% | 1747 |
|
|
2021
Q3 | $46K | Buy |
+8,815
| New | +$46K | ﹤0.01% | 1717 |
|
|
2021
Q2 | – | Sell |
-21,583
| Closed | -$99K | – | 1977 |
|
|
2021
Q1 | $99K | Buy |
+21,583
| New | +$99K | ﹤0.01% | 1206 |
|
|
2020
Q4 | – | Sell |
-18,161
| Closed | -$53K | – | 1858 |
|
|
2020
Q3 | $53K | Buy |
18,161
+6,791
| +60% | +$19.8K | ﹤0.01% | 1170 |
|
|
2020
Q2 | $52K | Sell |
11,370
-1,360
| -11% | -$6.22K | ﹤0.01% | 1217 |
|
|
2020
Q1 | $49K | Buy |
12,730
+8,960
| +238% | +$34.5K | ﹤0.01% | 1172 |
|
|
2019
Q4 | $14K | Buy |
+3,770
| New | +$14K | ﹤0.01% | 1322 |
|